Authored by Qiong Gao, et al., and presented at SLAS 2023
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Berkeley Lights Software Suite 2.4 upgrade is loaded with customer-requested features that focus on reduced touchpoints and more intuitive data analysis.
Watch a 1-hour webinar from the 2018 Antibody Engineering & Therapeutics Digital Week titled, “Emerging Technologies for Finding Rare Antibodies,” featuring scientists from Berkeley Lights and Teva Pharmaceuticals.